Latest revenue
$149.4M
as of 2026-03-31
Latest net income
$63.7M
as of 2026-03-31
Net margin
42.7%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think CPRX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $3.83B
- Enterprise value
- $3.07B
- P/E (trailing)
- 17.9×
- Forward P/E
- —
- P/B
- 3.78×
- Dividend yield
- 0.0%
- 52-wk high
- $32.56
- 52-wk low
- $19.05
- Beta
- —
- Shares out
- 122.4M
5-year trend
What this company does
Item 1. Business Overview We are a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. We currently sell three commercial stage drug products, FIRDAPSE® (amifampridine), AGAMREE® (vamorolone), and FYCOMPA® (perampanel). We are also currently seeking to further expand our product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept. With an unwavering patient focus…
AI summary unavailable — showing raw filing excerpt
Generated from CPRX's filing dated 2026-02-25
Key risks
Item 1A. Risk Factors Risk Factors Summary We are providing the following summary of the risk factors contained in our Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the full risk factors contained in this Form 10-K in their entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from our recent results or from our anticipated future results. Risks Related to our Business and the Marketing of Approved Products •Our success depends on the successful commercialization of our drug products. To the extent that our drug products are…
AI summary unavailable — showing raw filing excerpt
Generated from CPRX's filing dated 2026-02-25
Profitability
Operating margin
43.8%
10.3%Net margin
36.4%
9.2%Return on equity
22.5%
0.3%Return on assets
19.4%
0.9%Leverage
Debt / equity
0.16×
7.8%Debt / assets
13.6%
6.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $149.4M | +5.6% | $63.7M | +12.3% | 42.7% |
Q4 2025 2025-12-31 | $152.6M | +7.6% | $52.7M | -5.8% | 34.5% |
Q3 2025 2025-09-30 | $148.4M | +15.3% | $52.8M | +20.3% | 35.6% |
Q2 2025 2025-06-30 | $146.6M | +19.4% | $52.1M | +27.7% | 35.6% |
Q1 2025 2025-03-31 | $141.4M | +43.6% | $56.7M | +143.8% | 40.1% |
Q4 2024 2024-12-31 | $141.8M | — | $55.9M | — | 39.4% |
Q3 2024 2024-09-30 | $128.7M | +25.3% | $43.9M | +242.6% | 34.1% |
Q2 2024 2024-06-30 | $122.7M | +23.2% | $40.8M | +8.0% | 33.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on CPRX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$11.3M
Net activity
−$11.3M
Distinct insiders
8
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2025-12-12 | Molly Harper Director | Sale | 15,527 | $23.20 | $360.2K | |
| 2025-12-12 | Molly Harper Director | Sale | 4,473 | $23.73 | $106.2K | |
| 2025-12-12 | Molly Harper Director | Sale | 6,746 | $23.06 | $155.6K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CPRX
Institutional value
$1.39B
Total shares held
57.9M
Distinct holders
248
-122 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 18.8M | $464.9M | +147.7K (+0.8%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 5.1M | $126.8M | — | New |
| 3 | DIMENSIONAL FUND ADVISORS LP | 3.4M | $84.9M | +433.3K (+14.5%) | Added |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.5M | $61.3M | — | New |
| 5 | ROYCE & ASSOCIATES LP | 2.1M | $51.7M | +179.1K (+9.4%) | Added |
| 6 | Boston Partners | 1.7M | $42.4M | +480.2K (+39.0%) | Added |
| 7 | KENNEDY CAPITAL MANAGEMENT LLC | 1.2M | $29.7M | -10.1K (-0.8%) | Trimmed |
| 8 | UBS Group AG | 986.1K | $24.4M | +337.1K (+51.9%) | Added |
| 9 | VANGUARD FIDUCIARY TRUST CO | 802.6K | $19.9M | — | New |
| 10 | Invesco Ltd. | 752.8K | $18.6M | -540.6K (-41.8%) | Trimmed |
| 11 | SYSTEMATIC FINANCIAL MANAGEMENT LP | 747.5K | $18.5M | +24.3K (+3.4%) | Added |
| 12 | FEDERATED HERMES, INC. | 740.3K | $18.3M | +76.5K (+11.5%) | Added |
| 13 | Bank of New York Mellon Corp | 682.3K | $16.9M | -18.4K (-2.6%) | Trimmed |
| 14 | PRINCIPAL FINANCIAL GROUP INC | 676.0K | $16.7M | -7.7K (-1.1%) | Trimmed |
| 15 | Swedbank AB | 616.1K | $15.3M | -616.1K (-50.0%) | Trimmed |
| 16 | Voya Investment Management LLC | 589.9K | $14.6M | +22.4K (+4.0%) | Added |
| 17 | IMC-Chicago, LLC | 563.7K | $14.0M | — | New |
| 18 | JANE STREET GROUP, LLC | 545.2K | $13.5M | +279.0K (+104.8%) | Added |
| 19 | Public Sector Pension Investment Board | 526.3K | $13.0M | +33.4K (+6.8%) | Added |
| 20 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 479.0K | $11.9M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CPRX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.